AntiPlatelet Trialists Collaboration

Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of antiplatelet treatment. Part I prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994 308 81-106. 

Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy— III reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994 308 235-246. 

Preparations from plant materials containing salicylate have been used to treat pain and fever (Stone, 1763) from ancient times into the nineteenth century, when synthetic salicylic acid was synthesized in Germany and used for the same purposes. Acetyl salicylate, aspirin, synthesized as a prodrug for salicylate, was introduced by Bayer in 1899 (Dreser, 1899) and is still widely used to treat pain, fever, and inflammation. In low doses aspirin is also used by many to reduce the incidence of heart attacks by an antithrombotic effect (Antiplatelet Trialists Collaboration, 1994). Eventually, other drugs with therapeutic effects similar to those of aspirin were introduced, including indomethacin, ibuprofen, and naproxen. These... 

Antiplatelet Trialists Collaboration Secondary prevention ofvascular disease by prolonged antiplatelet treatment Brit Med. J. 296 320,1988... 

Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatdet therapy... 

Collins R, Baigent C, Sandercock P, Peto R, for the Antiplatelet Trialists Collaboration. Antiplatelet... 

Antiplatelet Trialists Collaboration 1994 British Medical Journal 308 81. 

Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ (Clin Res Ed) 1988 296(6618) 320-31. 

Antiplatelet Trialists Collaboration. (1994) Collaborative overview of randomised trials of antiplatelet therapy - II Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br. Med.J.. 308.159-168. 

Antiplatelet Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002 324 71-86. 

The final analysis of the Adenomatous Polyp Prevention on Vioxx (APPROVe) study (n = 2587 patients rofecoxib 25 mg, n = 1287 and placebo, n = 1300) included the combined incidence ofnon-fatal myocardial infarction, non-fatal stroke, and death from cardiovascular, hemorrhagic, and unknown causes (Antiplatelet Trialists Collaboration, APTC, combined end-point) and found that 59 individuals had an APTC combined end-point in the rofecoxib 25 mg group versus 34 in the placebo group (HR = 1.79 95% Cl = 1.17, 2.73) [13 ]. 

A protocol from a clinical trial on the CV safety of celecoxib compared to nsNSAIDs in patients with osteoarthritis or rheumatoid arthritis from Scotland, England, Denmark and the Netherlands was published. The primary endpoint is the first occurrence of hospitalisation or death for the AntiPlatelet Trialists Collaboration (APTC) CV endpoint of nonfatal myocardial infarction, nonfatal stroke or CV death. Secondary endpoints include (1) first hospitalisation or death for upper GI ulcer complications (bleeding, perforation or obstruction) (2) first occurrence of hospitalized upper GI ulcer complications or APTC endpoint (3) first hospitalisation for heart failure (4) first hospitalisation for APTC endpoint plus heart failure (5) all-cause mortality and (6) first hospitalisation for new or worsening renal failure. Patients are randomized to receive celecoxib or their previous nsNSAlD. Results of the trial are expected by 2014 [13 j. 

Cardiovascular Heart The incidence of Antiplatelet Trialists Collaboration and arterial thromboembolic events (ATEs) were 2.7% in the sham group (one acute myocardial infarction and one carotid artery stenosis) and 0.9% in the treatment group (one myocardial infarction) [5]. 

---